Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Open-market sale VP, Chief Accounting Officer sold 2,012 shares at $19.01 ($38,248)
  2. 10-Q Report Quarterly Report
  3. 8-K Event Results of operations
  4. 4 Grant or award EVP, Chief Financial Officer acquired 66,324 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. S-8 Other Securities Offered to Employees in Benefit Plans
  7. 4 Open-market sale EVP, Chief Technical Officer sold 405 shares at $22.93 ($9,287)
  8. 4 Grant or award VP, PAO and Interim PFO acquired 17,801 shares (grant or award)
  9. 8-K Event Executive or director change · Regulation FD disclosure
  10. 4 Planned sale Director sold 1,505 shares at $25.00 ($37,625)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Grant or award Director acquired 15,409 shares (grant or award)
  13. 8-K Event Executive or director change · Regulation FD disclosure
  14. 4 Grant or award Director acquired 7,737 shares (grant or award)
  15. 4 Grant or award Director acquired 7,737 shares (grant or award)
  16. 4 Grant or award Director acquired 7,737 shares (grant or award)
  17. 4 Grant or award Director acquired 7,737 shares (grant or award)
  18. 4 Grant or award Director acquired 7,737 shares (grant or award)
  19. 4 Grant or award Director acquired 7,737 shares (grant or award)
  20. 8-K Event Bylaws or fiscal year change · Shareholder vote results

Page 8 of 37 · 725 filings